Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of September 2025, with a specific report date of September 4, 2025. The filing serves to disseminate a press release regarding clinical efficacy data for the Company's ProSense® technology in treating abdominal wall endometriosis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical news rather than financial performance.
Material Changes
The material change reported is the announcement of clinical results indicating that IceCure's ProSense® technology substantially reduces abdominal wall endometriosis pain with high procedural efficacy. No financial changes versus prior periods are disclosed in this text.
Guidance, Outlook, and Risks
Management commentary is limited to the press release title and the incorporation of the release into existing Registration Statements (Form F-3 and Form S-8). The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the general context of the clinical announcement.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed clinical data and study parameters.
- Confirm the incorporation of the press release into active Registration Statements (Nos. 333-258660, 333-267272, 333-270982, 333-264578, 333-262620, and 333-281587).
- Review subsequent filings for any financial impact or strategic shifts resulting from the clinical efficacy announcement.